|
WO2007047282A1
|
|
Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
|
|
EA008666B1
|
|
Modified pictet-spengler reaction and products prepared therefrom
|
|
UA78839C2
|
|
Modified pictet-spengler reaction and products prepared therefrom
|
|
US2003144296A1
|
|
Daily treatment for erectile dysfunction using a PDE5 inhibitor
|
|
MXPA03011167A
|
|
Carboline derivatives as pdev inhibitors.
|
|
MXPA03011081A
|
|
Carboline derivatives as pde-5 inhibitors.
|
|
WO02098428A1
|
|
Tetracyclic compounds as pde5-inhibitors
|
|
CA2445625A1
|
|
Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives
|
|
CA2441792A1
|
|
Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction
|
|
EP1360186A2
|
|
Carboline derivatives
|
|
AU2002246728A1
|
|
Carboline derivatives
|
|
EP1366050A2
|
|
Condensed pyrazindione derivatives as pde inhibitors
|
|
MXPA03003971A
|
|
Indole derivatives as pde5-inhibitors.
|
|
AU1342102A
|
|
Chemical compounds
|
|
US6962918B2
|
|
Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
|
|
US6838456B2
|
|
Condensed pyridoindole derivatives
|
|
BR0113644A
|
|
Uses of pde5 inhibitor in the treatment of migraine
|
|
US7034027B2
|
|
Fused heterocyclic derivatives as phosphodiesterase inhibitors
|
|
EP1294721A1
|
|
Cyclic gmp-specific phosphodiesterase inhibitors
|
|
MXPA02012054A
|
|
Tetracyclic diketopiperazine compounds as pdev inhibitors.
|
